FEASIBILITY STUDIES BEFORE PRODUCT DEVELOPMENT CONTRACTS SMOOTH NEGOTIATIONS, MASS. BIOTECH SPEAKERS SAY; LICENSING CORE TECHNOLOGY NOT UNTHINKABLE
Executive Summary
"Feasibility arrangements" could be an avenue for biotechnology and pharmaceutical companies to become comfortable with one another before signing a collaborative or licensing agreement, Alkermes CEO Richard Pops and Merck VP-Corporate Licensing Elizabeth Wyatt said at the Massachusetts Biotechnology Council's annual meeting March 15 in Boston.